聚桂醇治疗口腔颌面部血管瘤的临床观察

Lauromacrogol clinical experience of oral and maxillofacial hemangioma

目的探讨聚桂醇治疗口腔颌面部血管瘤的临床疗效。方法 98例口腔和目标血管瘤患者随机分组,49例对照组患者给予平阳霉素、地塞米松及利多卡因瘤体内注射,49例研究组患者在上述治疗的基础上增加聚桂醇注射液,比较两组患者治愈率及不良反应发生率。结果研究组患者的临床治疗有效率为98%,不良发应发生率仅为6.1%。均优于对照组,差异有统计学意义(P﹤0.05)。结论聚桂醇治疗口腔颌面部血管瘤可提高临床治疗效果,并且该药不良反应小,疗效确切。

Objective To evaluate the clinical efficacy of oral and maxillofacial hemangioma with lauromacrogol. Methods 98 cases of oral and maxillofacial hemangioma patients were randomized, 49 patients in the control group were treated with PYM and dexamethasone.49 patients in the research group treated lauromacrogol addition, compared two groups of patients the cure rate and incidence of adverse reactions. Results patients in the research group treated with an effective rate of 98%, incidence of adverse reactions was only 6.1%. Both were better than the control group. The difference was statistically significant（P﹤0.05）. Conclusion lauromacrogol treatment of oral and maxillofacial hemangioma can improve clinical outcomes, and the drug adverse reaction is small.